Home › Encyclopedia › Cibinetide (ARA290): Research Status and Clinical Trial Overview
Research / Unapproved

Cibinetide (ARA290): Research Status and Clinical Trial Overview

Molecular formulaC51H84N16O21
Molecular weight1257.3 g/mol
Registered trials4
PubChem CID91810664

What cibinetide is

Cibinetide, also known as ARA290, is a synthetic peptide with the molecular formula C51H84N16O21 and a molecular weight of approximately 1,257.3 g/mol (PubChem CID 91810664). It has no FDA-approved label, no approved brand name, and no approved indication. Cibinetide is classified as an investigational compound and is studied only in research and clinical trial settings.

Trial footprint

Four clinical trials involving cibinetide are registered. Among the trials on record, a Phase 2 study examined its use for diabetic macular oedema but was terminated. A combined Phase 1/Phase 2 study assessed cognitive and neural effects and reached completed status, and a separate Phase 2 study evaluated corneal nerve fiber density and neuropathic symptoms in subjects with sarcoidosis, which also completed. These records describe trial design and status only, not outcomes or proven effects.

FAQ

Is cibinetide FDA approved?
No. Cibinetide, also called ARA290, has no FDA-approved label or indication. It remains classified as an investigational compound studied only in research settings.
What is cibinetide?
Cibinetide is a synthetic peptide with the molecular formula C51H84N16O21 and a molecular weight of about 1,257.3 g/mol. It is also referred to by the research name ARA290.
What conditions has cibinetide been studied for?
Registered trials have examined cibinetide in contexts such as diabetic macular oedema, cognitive and neural effects, and corneal nerve fiber density with neuropathic symptoms in sarcoidosis. One of these trials was terminated and others reached completed status, but this does not establish efficacy.
How many clinical trials have studied cibinetide?
Four clinical trials involving cibinetide are currently registered, spanning early-phase and mid-phase designs.
Are there known side effects of cibinetide?
No adverse event report data is available for cibinetide at this time, so no side effect pattern can be summarized.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-11-07